Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Saphia Alkali
Hanoi, Vietnam
- Ownership
- Private
- Development stage
- Other
01
Overview
Saphia Alkali's supplements—including Saphia Alkali K90—have shown potential benefits in animal models for tumor reduction and are marketed for supporting metabolic, immune, gastrointestinal, and joint health. Studies in mice indicate potential antitumor and supportive effects on hematological, biochemical, and tumor parameters, though human clinical validation is not published.
- Therapeutic areas
- ImmunologyRheumatologyGastroenterologyMetabolic DisordersOncology
- Modalities
- Herbal productSmall molecule
- Industry
- Food & Nutrition
02
Partnerships
Philux Global Group Inc. (formerly PHI Group Inc.)
Beyond the preview
Go deeper on Saphia Alkali.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saphia Alkali.